Clinical Trial Update: EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) [Phase 3]

View source ↗

Summary

This clinical trial update reports efficacy and safety results from the EXTEND III Phase 3 study of ranibizumab in patients with subfoveal choroidal neovascular…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Novartis | Conditions: Choroidal Neovascularization, Age-Related Macular Degeneration | Phase 3 | Status: COMPLETED